MedTrace Logo

Evaluate the Effectiveness and Toxicity of Adjuvant Ultra-hypofractionated Radiotherapy for Breast Cancer

NCT05850637 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2024-04-04

No results posted yet for this study

Summary

Prospective phase 2 study to evaluate the safety and efficacy of ultra-hypofractionated adjuvant radiotherapy in 5 fractions of 5.7 Gy in patients aged over 65 years.

Conditions

  • Breast Cancer Female

Interventions

RADIATION

adjuvant ultra-hypofractionated radiotherapy

adjuvant ultra-hypofractionated radiotherapy for the treatment of early and locally advanced breast cancer

Sponsors & Collaborators

  • Prevent Senior Institute

    lead OTHER

Principal Investigators

  • Marcel MF Fang, MD · Instituto de Pesquisa Prevent Senior

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
65 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-30
Primary Completion
2021-02-11
Completion
2023-04-01

Countries

  • Brazil

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05850637 on ClinicalTrials.gov